Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs
RegulatoryapprovedBEXLUTRYPositive
AI Analysis
Summary
Curium announced FDA approval of BEXLUTRY (lutetium Lu 177 dotatate injection) for adults with SSTR-positive GEP-NETs, marking the first radioligand equivalent and first radioligand therapy from Curium to receive FDA approval.
Outcome Details
FDA approval for BEXLUTRY (lutetium Lu 177 dotatate injection) for treatment of SSTR-positive GEP-NETs in adults. First radioligand equivalent and first radioligand therapy from Curium approved by FDA.
Importance:9/10
Sentiment:
0.95
FDA approvalradioligand therapyoncologyneuroendocrine tumorsfirst-in-class
Related Companies
Read the original article
Published by GlobeNewswire Pharma on September 14, 2026 9:49 PM